Genmab — Maj 2026
-
NICE issues Final Draft Guidance recommending that RYBREVANT
▼ (amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/nice-guidance-rybrevant-nsclc-egfr-exon20-managed-access -
Denecimig excels at reducing bleeds in hemophilia A patients: Study https://hemophilianewstoday.com/news/denecimig-excels-reducing-bleeds-hemophilia-a-patients/
-
The study of GEN1057 has been terminated due to marginal anti-tumor activity not supporting further development, Ref ClinicalTrials (NCT06573294) 8/5 2026. This was one of the 100% owned Genmab antibodies. The study started 28/8 2024 and stopped after enrolling 23 patients.
-
Genmab får gentaget "køb" hos Jefferies efter frustrationsreaktioner på forskningsnyt https://proinvestor.com/investornyt/1442956/genmab-far-gentaget-kob-hos-jefferies-efter-frustrationsreaktioner-pa-forskningsnyt
-
Stockwatch DK
@StockwatchDK
$GMAB
UBS reiterates its Buy rating on Genmab with a price target of DKK 2,600, saying the Q1 results were broadly in line with expectations. https://x.com/StockwatchDK/status/2053765010724159767 -
RYBREVANT
▼ (amivantamab) with LAZCLUZE
▼ (lazertinib) is accepted for use within NHS Scotland as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/rybrevant-amivantamab-with-lazcluze-lazertinib-is-accepted-for-use-within-nhs-scotland -
Novo Nordisk er steget 30% på relativ kort tid - men hvad ligger bag stigningen? Hør også om DSV's AI-gevinster frem mod 2030, Genmab-kursfald, høje oliepriser samt meget mere i ugens afsnit af Investeringspodcasten. https://proinvestor.com/boards/132326
-
Interessant artikel om konkurrerende produkt til peto, hvor udvidelsen diskuteres https://seekingalpha.com/article/4904035-bicara-therapeutics-inc-bcax-presents-at-bank-of-america-global-healthcare-conference-2026
-
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6 https://www.sciencedirect.com/science/article/pii/S215226502600042X
-
Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation https://haematologica.org/article/view/14183 (click on PDF to read article)
-
University looking to test Dara in lung cancer... https://clinicaltrials.gov/study/NCT06015724 - don't want to bring up Hexabody-CD38 again, but...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind